Study Identifies Crucial Enzyme Driving Breast Cancer –

Looking to identify new strategies to prevent breast cancer recurrence, researchers supported by grants from Susan G. Komen, the National Institutes of Health, the National Cancer Institute?s core grant to Roswell Park, the Department of Defense, and the American Cancer Society and led by Subhamoy Dasgupta, PhD, Assistant Professor of Oncology in the Department of Cell Stress Biology at

Photo 1.0: Subhamoy Dasgupta, PhD, Assistant Professor of Oncology in the Department of Cell Stress Biology at Roswell Park Comprehensive Cancer Center.

Roswell Park Comprehensive Cancer Center, has identified two key proteins involved in glucose metabolism that could be targeted to prevent breast cancer metastasis and recurrence.

The team?s findings were published today in the journal Nature. [1]

Rapid growth and proliferation are hallmarks of cancer cells, which require a large amount of glucose to meet their energy needs.

Because the majority of advanced breast tumors are notably dependent on glucose metabolism, strategies that alter the metabolic pathways of cancer cells can be used to improve outcomes and prevent metastasis or recurrence in patients with breast cancer.

Illustration 1.0:? New research published in Nature shows that the interaction between two metabolic enzymes drives tumor growth.

Working with Bert O?Malley, MD, and other researchers from Baylor College of Medicine in Houston, where this work originated, Dasgupta screened over 600 proteins and identified PFKFB4, an enzymatic protein involved in the glucose metabolic pathway, as the strongest activator of SRC-3, a protein known to drive cancer progression and metastasis.

Breast cancer patients whose tumors express SRC-3 generally have a poor prognosis, suggesting that therapies targeting these two proteins or blocking their interaction could have a broad and significant impact on breast cancer treatment.

?The enzyme PFKFB4 acts as a molecular fulcrum stimulating the activation of SRC-3, which promotes growth of very aggressive metastatic tumors,? explains Dasgupta, first author on the study.

?Remarkably, we also found that the expression of PFKFB4 is significantly enhanced across all types of breast cancer,” he added.

“This research suggests that the development of strategies targeting the PFKFB4-SRC-3 pathway could be used to prevent the growth, recurrence and spread of many, if not all, types of breast cancer tumors,? Dasgupta concluded.


Last Editorial Review: April 3, 2018

Featured Image: Research Courtesy: ? 2010 – 2018 Fotolia. Used with permission. Photo 1.0: Subhamoy Dasgupta, PhD, Assistant Professor of Oncology in the Department of Cell Stress Biology at Roswell Park Comprehensive Cancer Center. Courtesy: ? 2010 – 2018 oswell Park Comprehensive Cancer Center. Used with permission. Illustration 1.0:? New research published in Nature shows that the interaction between two metabolic enzymes drives tumor growth. Courtesy: ? 2010 – 2018 oswell Park Comprehensive Cancer Center. Used with permission.

Copyright ? 2010 – 2018 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco?Zine, Oncozine and The Onco?Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.